PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ:STEM) today commented on the PLoS Medicine article published online February 17, 2009 describing a patient who developed “brain tumors” (glioneuronal neoplasms) after undergoing repeated transplants of “fetal neural stem cells” in Russia starting in 2001. StemCells wishes to state that, after careful review of the information available, the particular circumstances of this unfortunate case are neither comparable nor relevant to the ongoing clinical development of HuCNS-SC® cells, the Company’s proprietary human central nervous system stem cell product candidate.
